We enumerated the cancer types with TP53/RB1 co-mutations and investigated the patient outcome and the specific characteristics of cancer cells with TP53/RB1 co-mutations, especially the drugs that can and cannot be used to kill these cells. This evidence concerns the gene TP53 and cancer.